Oxford Biomedica plc (LON:OXB – Get Free Report) insider Michael Hayden acquired 10,000 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was purchased at an average cost of GBX 193 ($2.37) per share, for a total transaction of £19,300 ($23,701.34).
Oxford Biomedica Stock Up 8.7 %
Shares of Oxford Biomedica stock opened at GBX 210 ($2.58) on Wednesday. The stock’s fifty day moving average is GBX 260.64 and its 200-day moving average is GBX 360.34. The firm has a market capitalization of £203.24 million, a PE ratio of -328.13 and a beta of 1.02. The company has a quick ratio of 1.67, a current ratio of 3.32 and a debt-to-equity ratio of 57.10. Oxford Biomedica plc has a 12-month low of GBX 190.20 ($2.34) and a 12-month high of GBX 575 ($7.06).
Analysts Set New Price Targets
Separately, Liberum Capital dropped their price objective on Oxford Biomedica from GBX 350 ($4.30) to GBX 310 ($3.81) and set a “hold” rating on the stock in a research note on Tuesday, September 26th.
Oxford Biomedica Company Profile
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems.
- Five stocks we like better than Oxford Biomedica
- Canada Bond Market Holiday: How to Invest and Trade
- Analyst says Archer Aviation may double. Is it time to buy?
- Pros And Cons Of Monthly Dividend Stocks
- Alibaba’s bottom is in: Analysts see a monster rally ahead
- How to Invest in Music Stocks
- TripAdvisor is on AI-powered recovery from record lows
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.